These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 20956826)
1. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials. Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826 [TBL] [Abstract][Full Text] [Related]
2. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N; Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000 [TBL] [Abstract][Full Text] [Related]
3. From adjuvant therapy to breast cancer prevention: BCPT and STAR. Dunn BK; Ford LG Breast J; 2001; 7(3):144-57. PubMed ID: 11469927 [TBL] [Abstract][Full Text] [Related]
4. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ. Vogel VG; Costantino JP; Wickerham DL; Cronin WM Clin Cancer Res; 2003 Jan; 9(1 Pt 2):495S-501S. PubMed ID: 12538506 [TBL] [Abstract][Full Text] [Related]
5. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Lippman SM; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N; JAMA; 2006 Jun; 295(23):2727-41. PubMed ID: 16754727 [TBL] [Abstract][Full Text] [Related]
6. Breast cancer chemoprevention. Rosenbaum Smith SM; Osborne MP Am J Surg; 2000 Oct; 180(4):249-51. PubMed ID: 11113429 [TBL] [Abstract][Full Text] [Related]
7. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Vogel VG Expert Rev Anticancer Ther; 2009 Jan; 9(1):51-60. PubMed ID: 19105706 [TBL] [Abstract][Full Text] [Related]
8. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts. Vogel VG Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233 [TBL] [Abstract][Full Text] [Related]
9. Chemoprevention of breast cancer. Thomsen A; Kolesar JM Am J Health Syst Pharm; 2008 Dec; 65(23):2221-8. PubMed ID: 19020189 [TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Levine M; Moutquin JM; Walton R; Feightner J; CMAJ; 2001 Jun; 164(12):1681-90. PubMed ID: 11450210 [TBL] [Abstract][Full Text] [Related]
11. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force. Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250 [TBL] [Abstract][Full Text] [Related]
12. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. Land SR; Wickerham DL; Costantino JP; Ritter MW; Vogel VG; Lee M; Pajon ER; Wade JL; Dakhil S; Lockhart JB; Wolmark N; Ganz PA JAMA; 2006 Jun; 295(23):2742-51. PubMed ID: 16754728 [TBL] [Abstract][Full Text] [Related]
13. Chemoprevention for high-risk women: tamoxifen and beyond. Fabian CJ; Kimler BF Breast J; 2001; 7(5):311-20. PubMed ID: 11906441 [TBL] [Abstract][Full Text] [Related]
14. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. Freedman AN; Yu B; Gail MH; Costantino JP; Graubard BI; Vogel VG; Anderson GL; McCaskill-Stevens W J Clin Oncol; 2011 Jun; 29(17):2327-33. PubMed ID: 21537036 [TBL] [Abstract][Full Text] [Related]
15. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Nelson HD; Smith ME; Griffin JC; Fu R Ann Intern Med; 2013 Apr; 158(8):604-14. PubMed ID: 23588749 [TBL] [Abstract][Full Text] [Related]
16. The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1). Wolmark N; Dunn BK Ann N Y Acad Sci; 2001 Dec; 949():99-108. PubMed ID: 11795386 [TBL] [Abstract][Full Text] [Related]
17. A review of selective estrogen receptor modulators and national surgical adjuvant breast and bowel project clinical trials. Smith RE Semin Oncol; 2003 Oct; 30(5 Suppl 16):4-13. PubMed ID: 14613021 [TBL] [Abstract][Full Text] [Related]
18. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention. Vogel VG Curr Drug Targets; 2011 Dec; 12(13):1874-87. PubMed ID: 21158712 [TBL] [Abstract][Full Text] [Related]
19. Exemestane for primary prevention of breast cancer in postmenopausal women. Zhang Y; Simondsen K; Kolesar JM Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103 [TBL] [Abstract][Full Text] [Related]